1	InterMune	intermune	NNP	p2=VB	2	nn	_
2	Inc	inc	NNP	_	0	root	_
3	.	.	.	_	2	punct	_

1	(	(	-LRB-	_	4	punct	_
2	ITMN	itmn	NNP	p2=NN	4	nsubj	4:A1
3	)	)	-RRB-	_	4	punct	_
4	rose	rise	VBD	p2=NN|pb=rise.01	0	root	_
5	in	in	IN	_	4	prep	4:AM-LOC
6	early	early	JJ	_	7	amod	_
7	trading	trading	NN	_	5	pobj	_
8	on	on	IN	_	4	prep	4:AM-CAU
9	investor	investor	NN	_	10	nn	_
10	optimism	optimism	NN	_	8	pobj	12:A2=LOC
11	that	that	WDT	p2=IN	12	nsubj	12:R-A2
12	results	result	VBZ	pb=result.01	10	rcmod	_
13	from	from	IN	_	12	prep	12:A1=PPT
14	a	a	DT	_	16	det	_
15	new	new	JJ	_	16	amod	_
16	study	study	NN	_	13	pobj	_
17	of	of	IN	_	16	prep	_
18	its	its	PRP$	_	22	poss	_
19	lung	lung	NN	_	20	nn	_
20	disease	disease	NN	_	22	nn	_
21	drug	drug	NN	_	22	nn	_
22	pirfenidone	pirfenidone	NN	p2=NNS	17	pobj	_
23	will	will	MD	_	24	aux	24:AM-MOD
24	lead	lead	VB	pb=lead.03	4	conj	_
25	to	to	IN	_	24	prep	24:A2=PRD
26	U.S.	u.s.	NNP	_	28	nn	_
27	regulatory	regulatory	JJ	_	28	amod	_
28	approval	approval	NN	_	25	pobj	_
29	.	.	.	_	4	punct	_

1	InterMune	intermune	NNP	_	2	nsubj	2:A1=PPT
2	gained	gain	VBD	pb=gain.01	0	root	_
3	5.9	0	CD	_	4	num	_
4	percent	percent	NN	_	2	dobj	2:A2=EXT
5	to	to	IN	_	2	prep	2:A4=GOL
6	$	$	$	_	7	nmod	_
7	36.32	0	CD	_	5	pobj	_
8	at	at	IN	_	2	prep	2:AM-TMP
9	9:07	0	CD	_	13	num	_
10	a.m.	a.m.	NN	p2=IN	13	nn	_
11	New	new	NNP	_	12	nn	_
12	York	york	NNP	_	13	nn	_
13	time	time	NN	_	8	pobj	_
14	.	.	.	_	2	punct	_

1	Pirfenidone	pirfenidone	NN	p2=NNP	4	nsubjpass	4:A1=PPT;14:A1=PPT
2	will	will	MD	_	4	aux	4:AM-MOD
3	be	be	VB	_	4	auxpass	_
4	submitted	submit	VBN	pb=submit.01	32	ccomp	32:A1=PPT
5	for	for	IN	_	4	prep	4:A3=PRP
6	approval	approval	NN	_	5	pobj	_
7	in	in	IN	_	4	prep	4:AM-TMP
8	the	the	DT	_	11	det	_
9	next	next	JJ	_	11	amod	_
10	few	few	JJ	_	11	amod	_
11	weeks	week	NNS	_	7	pobj	_
12	and	and	CC	_	4	cc	_
13	may	may	MD	_	14	aux	14:AM-MOD
14	be	be	VB	pb=be.01	4	conj	_
15	on	on	IN	_	14	prep	14:A2=PRD
16	the	the	DT	_	17	det	_
17	market	market	NN	_	15	pobj	_
18	in	in	IN	_	14	prep	14:AM-TMP
19	the	the	DT	_	21	det	_
20	first	#ord#	JJ	_	21	amod	_
21	quarter	quarter	NN	_	18	pobj	_
22	of	of	IN	_	21	prep	_
23	2015	0	CD	_	22	pobj	_
24	,	,	,	_	32	punct	_
25	the	the	DT	_	31	det	_
26	Brisbane	brisbane	NNP	p2=NNPS	31	nn	_
27	,	,	,	_	31	punct	_
28	California	california	NNP	_	30	hmod	_
29	-	-	HYPH	_	30	hyph	_
30	based	base	VBN	_	31	amod	_
31	company	company	NN	_	32	nsubj	32:A0
32	said	say	VBD	pb=say.01	0	root	_
33	in	in	IN	_	32	prep	32:AM-LOC
34	a	a	DT	_	36	det	_
35	regulatory	regulatory	JJ	_	36	amod	_
36	filing	filing	NN	_	33	pobj	_
37	.	.	.	_	32	punct	_

1	The	the	DT	_	2	det	_
2	drug	drug	NN	_	10	nsubjpass	14:A0=PAG;5:A1=PPT;10:A1=PPT
3	,	,	,	_	2	punct	_
4	also	also	RB	_	5	advmod	5:AM-DIS
5	known	know	VBN	pb=know.01	2	partmod	_
6	as	as	IN	_	5	prep	5:A2=PRD
7	Esbriet	esbriet	NNP	p2=NN	6	pobj	_
8	,	,	,	_	2	punct	_
9	is	be	VBZ	_	10	auxpass	_
10	approved	approve	VBN	pb=approve.01	0	root	_
11	in	in	IN	_	10	prep	10:AM-LOC
12	Europe	europe	NNP	_	11	pobj	_
13	to	to	TO	_	14	aux	_
14	treat	treat	VB	pb=treat.03	10	xcomp	10:A2=PRD
15	idiopathic	idiopathic	JJ	p2=RP	17	amod	_
16	pulmonary	pulmonary	JJ	_	17	amod	_
17	fibrosis	fibrosis	NN	_	14	dobj	14:A1=PPT
18	,	,	,	_	17	punct	_
19	a	a	DT	_	23	det	_
20	lung	lung	NN	_	22	hmod	_
21	-	-	HYPH	_	22	hyph	_
22	scarring	scar	VBG	p2=NN	23	amod	_
23	disease	disease	NN	_	17	conj	_
24	without	without	IN	_	14	prep	14:AM-MNR
25	a	a	DT	_	26	det	_
26	cure	cure	NN	_	24	pobj	29:A1=PPT
27	whose	whose	WP$	_	28	poss	_
28	cause	cause	NN	_	29	nsubj	29:R-A1
29	is	be	VBZ	pb=be.01	26	rcmod	_
30	unknown	unknown	JJ	_	29	acomp	29:A2=PRD
31	.	.	.	_	10	punct	_

1	The	the	DT	_	2	det	_
2	medicine	medicine	NN	_	4	nsubjpass	4:A1=PPT
3	was	be	VBD	_	4	auxpass	_
4	rejected	reject	VBN	pb=reject.01	0	root	_
5	in	in	IN	_	4	prep	4:AM-TMP
6	2010	0	CD	_	5	pobj	_
7	by	by	IN	_	4	agent	4:A0=PAG
8	U.S.	u.s.	NNP	_	9	nn	_
9	regulators	regulator	NNS	_	7	pobj	12:A0=PAG
10	,	,	,	_	9	punct	_
11	who	who	WP	_	12	nsubj	12:R-A0
12	asked	ask	VBD	pb=ask.02	9	rcmod	_
13	for	for	IN	_	12	prep	12:A1=PPT
14	a	a	DT	_	16	det	_
15	new	new	JJ	_	16	amod	_
16	trial	trial	NN	_	13	pobj	_
17	on	on	IN	_	16	prep	_
18	effectiveness	effectiveness	NN	_	17	pobj	_
19	.	.	.	_	4	punct	_

1	Pirfenidone	pirfenidone	NN	p2=NNP	13	nsubj	13:A0=CAU
2	and	and	CC	_	1	cc	_
3	another	another	DT	_	4	det	_
4	drug	drug	NN	_	1	conj	_
5	,	,	,	_	4	punct	_
6	Boehringer	boehringer	NNP	_	8	nn	_
7	Ingelheim	ingelheim	NNP	_	8	nn	_
8	GmbH	gmbh	NNP	_	10	poss	_
9	's	's	POS	_	8	possessive	_
10	nintedanib	nintedanib	NN	p2=NNP	4	appos	_
11	,	,	,	_	4	punct	_
12	both	both	CC	p2=DT	4	appos	_
13	showed	show	VBD	pb=show.01	0	root	_
14	progress	progress	NN	_	13	dobj	13:A1=PPT
15	in	in	IN	_	14	prep	_
16	slowing	slow	VBG	pb=slow.01	15	pcomp	_
17	the	the	DT	_	18	det	_
18	disease	disease	NN	_	20	poss	_
19	's	's	POS	_	18	possessive	_
20	progression	progression	NN	_	16	dobj	16:A1=PPT
21	,	,	,	_	13	punct	_
22	according	accord	VBG	_	13	prep	13:AM-ADV
23	to	to	IN	_	22	prep	_
24	a	a	DT	_	25	det	_
25	report	report	NN	_	23	pobj	_
26	in	in	IN	_	25	prep	_
27	the	the	DT	_	30	det	_
28	New	new	NNP	_	29	nn	_
29	England	england	NNP	_	30	nn	_
30	Journal	journal	NNP	_	26	pobj	_
31	of	of	IN	_	30	prep	_
32	Medicine	medicine	NNP	_	31	pobj	_
33	.	.	.	_	13	punct	_

1	The	the	DT	_	2	det	_
2	disease	disease	NN	_	3	nsubj	3:A0=CAU
3	causes	cause	VBZ	pb=cause.01	0	root	_
4	tissue	tissue	NN	_	3	dobj	3:A1=PPT
5	deep	deep	RB	p2=JJ	6	advmod	_
6	in	in	IN	_	3	prep	_
7	the	the	DT	_	8	det	_
8	lungs	lung	NNS	_	6	pobj	_
9	to	to	TO	_	10	aux	_
10	become	become	VB	pb=become.01	3	advcl	_
11	increasingly	increasingly	RB	_	12	advmod	_
12	thick	thick	JJ	_	10	acomp	10:A2=PRD
13	and	and	CC	_	12	cc	_
14	stiff	stiff	JJ	_	12	conj	_
15	,	,	,	_	10	punct	_
16	or	or	CC	_	10	cc	_
17	scarred	scar	VBN	p2=JJ|pb=scar.01	10	conj	_
18	,	,	,	_	17	punct	_
19	over	over	IN	_	17	conj	_
20	time	time	NN	_	19	pobj	_
21	,	,	,	_	3	punct	_
22	according	accord	VBG	_	3	prep	_
23	to	to	IN	_	22	prep	_
24	the	the	DT	_	26	det	_
25	National	national	NNP	_	26	nn	_
26	Heart	heart	NNP	p2=NN	23	pobj	_
27	,	,	,	_	26	punct	_
28	Lung	lung	NNP	_	26	conj	_
29	and	and	CC	_	28	cc	_
30	Blood	blood	NNP	p2=NN	31	nn	_
31	Institute	institute	NNP	_	28	conj	_
32	.	.	.	_	3	punct	_

1	When	when	WRB	_	3	advmod	3:R-AM-TMP
2	that	that	DT	_	3	nsubj	3:A1=PPT
3	happens	happen	VBZ	pb=happen.01	6	advcl	6:AM-TMP
4	,	,	,	_	6	punct	_
5	it	it	PRP	_	6	nsubj	6:A0=PAG;19:A0=CAU
6	inhibits	inhibit	VBZ	pb=inhibit.01	0	root	_
7	the	the	DT	_	8	det	_
8	ability	ability	NN	_	6	dobj	6:A1=PPT
9	of	of	IN	_	8	prep	_
10	the	the	DT	_	11	det	_
11	lungs	lung	NNS	_	9	pobj	_
12	to	to	TO	_	13	aux	_
13	move	move	VB	pb=move.01	8	infmod	_
14	oxygen	oxygen	NN	_	13	dobj	13:A1=PPT
15	into	into	IN	_	13	prep	13:A2=GOL
16	the	the	DT	_	17	det	_
17	bloodstream	bloodstream	NN	p2=NNS	15	pobj	_
18	,	,	,	_	6	punct	_
19	limiting	limit	VBG	pb=limit.01	6	advcl	6:AM-ADV
20	the	the	DT	_	21	det	_
21	amount	amount	NN	_	19	dobj	19:A1=PPT;23:A1=PPT
22	that	that	WDT	_	23	nsubj	23:R-A1
23	gets	get	VBZ	pb=get.05	21	rcmod	_
24	to	to	IN	_	23	prep	23:A2=GOL
25	the	the	DT	_	26	det	_
26	brain	brain	NN	_	24	pobj	_
27	and	and	CC	_	26	cc	_
28	other	other	JJ	_	29	amod	_
29	organs	organ	NNS	_	26	conj	_
30	.	.	.	_	6	punct	_

1	It	it	PRP	_	2	nsubj	2:A1=PPT
2	's	be	VBZ	pb=be.01	0	root	_
3	a	a	DT	_	4	det	_
4	malady	malady	NN	p2=NNP	2	attr	6:A1=PPT;2:A2=PRD
5	mostly	mostly	RB	_	6	advmod	6:AM-ADV
6	found	find	VBN	pb=find.01	4	partmod	_
7	in	in	IN	_	6	prep	6:AM-LOC
8	middle	middle	NN	p2=JJ	10	hmod	_
9	-	-	HYPH	_	10	hyph	_
10	aged	aged	JJ	_	13	amod	_
11	and	and	CC	_	10	cc	_
12	older	old	JJR	p2=JJ	10	conj	_
13	adults	adult	NNS	_	7	pobj	_
14	.	.	.	_	2	punct	_

1	Nintedanib	nintedanib	NNP	p2=CD	5	nsubjpass	5:A1=PPT;10:A1=PPT
2	and	and	CC	_	1	cc	_
3	pirfenidone	pirfenidone	NN	p2=NNS	1	conj	_
4	were	be	VBD	_	5	auxpass	_
5	studied	study	VBN	pb=study.01	0	root	_
6	separately	separately	RB	_	5	advmod	5:AM-MNR
7	and	and	CC	_	5	cc	_
8	were	be	VBD	_	10	auxpass	_
9	not	not	RB	_	10	neg	10:AM-NEG
10	compared	compare	VBN	pb=compare.01	5	conj	_
11	with	with	IN	_	10	prep	10:A2=PPT
12	each	each	DT	_	13	det	_
13	other	other	JJ	_	11	pobj	_
14	.	.	.	_	5	punct	_

1	Data	data	NNP	p2=NNS	6	nsubj	6:A0=PAG
2	from	from	IN	_	1	prep	_
3	the	the	DT	_	5	det	_
4	Boehringer	boehringer	NNP	_	5	nn	_
5	trial	trial	NN	_	2	pobj	_
6	has	have	VBZ	pb=have.03	34	ccomp	34:A1=PPT
7	a	a	DT	_	11	det	_
8	"	"	``	_	11	punct	_
9	very	very	RB	p2=JJ	10	advmod	_
10	convincing	convincing	JJ	_	11	amod	_
11	basis	basis	NN	_	6	dobj	6:A1=PPT
12	,	,	,	_	34	punct	_
13	"	"	''	p2=``	34	punct	_
14	Susanne	susanne	NNP	_	15	nn	_
15	Stowasser	stowasser	NNP	_	5	appos	_
16	,	,	,	_	15	punct	_
17	the	the	DT	_	18	det	_
18	Ingelheim	ingelheim	NNP	p2=NNPS	15	appos	_
19	,	,	,	_	34	punct	_
20	Germany	germany	NNP	_	22	hmod	_
21	-	-	HYPH	_	22	hyph	_
22	based	base	VBN	_	23	amod	_
23	company	company	NN	_	26	poss	_
24	's	's	POS	_	23	possessive	_
25	team	team	NN	_	26	nn	_
26	leader	leader	NN	_	34	nsubj	34:A0
27	of	of	IN	_	26	prep	_
28	global	global	JJ	_	32	amod	_
29	medical	medical	JJ	_	30	amod	_
30	affairs	affair	NNS	_	32	hmod	_
31	-	-	HYPH	p2=:	32	hyph	_
32	respiratory	respiratory	NN	p2=JJ	27	pobj	_
33	,	,	,	_	34	punct	_
34	said	say	VBD	pb=say.01	0	root	_
35	in	in	IN	_	34	prep	34:AM-LOC
36	an	an	DT	_	37	det	_
37	interview	interview	NN	_	35	pobj	_
38	.	.	.	_	34	punct	_

1	Judith	judith	NNP	_	3	nn	_
2	von	von	NNP	_	3	nn	_
3	Gordon	gordon	NNP	_	8	nsubj	8:A0
4	,	,	,	_	3	punct	_
5	another	another	DT	_	6	det	_
6	spokeswoman	spokeswoman	NN	_	3	appos	_
7	,	,	,	_	3	punct	_
8	said	say	VBD	pb=say.01	0	root	_
9	the	the	DT	_	12	det	_
10	closely	closely	RB	_	11	advmod	11:AM-MNR
11	held	hold	VBN	pb=hold.01	12	amod	_
12	company	company	NN	_	14	nsubj	14:A0=PAG;11:A1=PPT
13	will	will	MD	_	14	aux	14:AM-MOD
14	file	file	VB	pb=file.01	8	ccomp	8:A1=PPT
15	for	for	IN	_	14	prep	14:A1=PPT
16	approval	approval	NN	_	15	pobj	_
17	this	this	DT	_	18	det	_
18	year	year	NN	_	14	npadvmod	14:AM-TMP
19	.	.	.	_	8	punct	_

1	Geoff	geoff	NNP	_	2	nn	_
2	Curtis	curtis	NNP	_	9	nsubj	9:A1=PPT
3	,	,	,	_	2	punct	_
4	a	a	DT	_	5	det	_
5	spokesman	spokesman	NN	_	2	appos	_
6	for	for	IN	_	5	prep	_
7	InterMune	intermune	NNP	_	6	pobj	_
8	,	,	,	_	9	punct	_
9	was	be	VBD	pb=be.01	0	root	_
10	n't	not	RB	_	9	neg	9:AM-NEG
11	immediately	immediately	RB	_	12	advmod	_
12	available	available	JJ	_	9	acomp	9:A2=PRD
13	for	for	IN	_	12	prep	_
14	an	an	DT	_	15	det	_
15	interview	interview	NN	_	13	pobj	_
16	.	.	.	_	9	punct	_

1	Press	press	NNP	p2=VB	2	nn	6:A0=PAG
2	spacebar	spacebar	NN	p2=VBP	0	root	6:A1=PPT
3	to	to	IN	p2=TO	2	prep	_
4	pause	pause	NN	_	3	pobj	_
5	and	and	CC	_	2	cc	_
6	continue	continue	VB	p2=VBP|pb=continue.01	2	conj	_
7	.	.	.	_	2	punct	_

1	Press	press	NNP	p2=VB	2	nsubj	2:A0;4:A0=PAG
2	esc	esc	VBD	p2=NN|pb=esc.01	0	root	_
3	to	to	TO	_	4	aux	_
4	stop	stop	VB	pb=stop.01	2	xcomp	2:A1
5	.	.	.	_	2	punct	_

1	U.S.	u.s.	NNP	_	2	nn	_
2	U.S.	u.s.	NNP	_	0	root	_

